DA
HRMY icon

Denali Advisors’s Harmony Biosciences HRMY Stock Holding History

Denali Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Buy
89,600
+29,700
+50% +$937K 0.33% 93
2026
Q1 		$1.68M Sell
59,900
-37,928
-39% -$1.24M 0.19% 126
2025
Q4 		$3.66M Sell
97,828
-4,200
-4% -$138K 0.41% 84
2025
Q3 		$2.81M Buy
102,028
+22,661
+29% +$781K 0.32% 99
2025
Q2 		$2.51M Hold
79,367
– – 0.26% 106
2025
Q1 		$2.63M Sell
79,367
-24,947
-24% -$894K 0.3% 103
2024
Q4 		$3.59M Buy
104,314
+52,814
+103% +$1.81M 0.38% 90
2024
Q3 		$2.06M Buy
51,500
+37,400
+265% +$1.31M 0.22% 125
2024
Q2 		$425K Buy
+14,100
New +$424K 0.12% 147

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Denali Advisors's HRMY Position: Q2 2026 in Review

Denali Advisors increased its Harmony Biosciences (HRMY) stake by 50% in Q2 2026, buying an estimated $937K and bringing the position to 89,600 shares worth $3.26M. The position accounts for 0.33% of the portfolio, ranked #93.

Denali Advisors first reported a position in HRMY in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.66M in Q4 2025. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Denali Advisors held 89,600 shares of Harmony Biosciences worth $3.26M as of Q2 2026.
  • Denali Advisors bought 29,700 Harmony Biosciences shares in Q2 2026, an estimated $937K.
  • Harmony Biosciences made up 0.33% of Denali Advisors's portfolio in Q2 2026, its #93 holding.
  • Denali Advisors first reported a position in Harmony Biosciences in Q2 2024 and has held it in 9 quarters since.
  • Denali Advisors's Harmony Biosciences position peaked at $3.66M in Q4 2025.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Denali Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.